Agennix Initiates Phase II Study of Sepsis Drug
Posted on: Wednesday, 23 April 2008, 12:00 CDT
Agennix has initiated a randomized, double-blind, placebo-controlled Phase II study of oral talactoferrin alfa in patients with severe sepsis.
The study is being supported by a Small Business Innovative Research grant awarded from the National Institutes of Health. The total amount of the grant, $3 million, will provide the financial resources necessary to conduct the 190-patient study, which is designed to evaluate the safety and activity of talactoferrin in patients with severe sepsis. Results from the trial are anticipated in mid-2009.
This is the first clinical trial of talactoferrin in sepsis and is based on both the mechanism of action of talactoferrin, and promising preclinical data demonstrating a significant reduction in mortality by talactoferrin in a variety of animal models of sepsis, including some that cause 100% mortality in untreated animals.
The Phase II trial, which has started enrollment, will be conducted at approximately 25 US centers with investigators who are said to be very experienced in conducting trials in severe sepsis.
Kalpalatha Guntupalli, principal investigator for the Phase II study, said: "Talactoferrin is a very promising compound with broad immunomodulatory and anti-inflammatory properties. We hope that the preclinical results translate to the drug showing activity in the Phase II study by reducing the number of deaths in patients with severe sepsis."
Source: Datamonitor
Related Articles
- ARYx Therapeutics Inc. Completes Enrollment in EmbraceAC Study -- Phase 2/3 Clinical Trial Comparing Anticoagulant ATI-5923 Against Warfarin
- Chelsea Therapeutics Begins Patient Dosing in Second Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension
- Repros Therapeutics Inc. Announces That Proellex Significantly Reduces Pain in a U.S. Phase 2 Clinical Trial in Women With Moderate to Severe Endometriosis
- Gentium Announces the Data Safety Monitoring Board Review of the Phase III Trial of Defibrotide to Treat Patients With Severe Veno-Occlusive Disease
- XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986
- Curis Provides Update on Ongoing Basal Cell Carcinoma Phase I Clinical Trial
- Altus Pharmaceuticals Presents Positive Data From Phase I Study of ALTU-238; First Patients Dosed in Phase II Trial in Adults With Growth Hormone Deficiency
- Phase 3 Clinical Trial Initiated for Cystic Fibrosis Patients With Pseudomonas
- CureTech Announces Encouraging Phase I Clinical Trial Results in Cancer Patients With Its Monoclonal Antibody CT-011
- Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-B(TM) in Patients With Rheumatoid Arthritis
 |
 |
User Comments (0)
RSS Feeds